Web-Banner-for-LNC.jpg

New FDA Drug Approvals - September 2022


tapinarof

Vtama

Pharmaceutical company: Dermavant Sciences, Inc.

Pharmacologic classification:Antipsoriatic

Therapeutic classification:Aryl hydrocarbon receptor agonist

AVAILABLE FORMS

Cream: 1%

INDICATIONS AND DOSAGES

Plaque psoriasis

Adults: Apply a thin layer to psoriatic skin lesions once daily.

CONTRAINDICATIONS AND CAUTIONS

  • Safety and efficacy in children haven’t been established.
  • Dialyzable drug: Unlikely.

PREGNANCY-LACTATION-REPRODUCTION

  • There are no adequate studies during pregnancy. Use during pregnancy only if the potential benefit justifies the fetal risk.
  • It isn’t known if this drug appears in human milk. Use during breastfeeding only if the potential benefit justifies the infant risk.

INTERACTIONS

None reported.

ADVERSE REACTIONS

CNS: headache.

EENT: nasopharyngitis.

Skin: folliculitis, contact dermatitis, pruritis.

Other: flulike syndrome.

Reactions in bold italics are life-threatening.

Released: September 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer